BRAFV600E and KIT Immunoexpression in Early-stage Melanoma

Overview

Journal An Bras Dermatol

Specialty Dermatology

Date 2019 Oct 24

PMID 31644622

Citations 1

Authors

Andressa Germano

Leonardo Cardili

Fernando Cintra Lopes Carapeto

Gilles Landman

Affiliations

Soon will be listed here.

Abstract

Melanoma is widely known as the most lethal skin cancer. Specific tumor-related mortality can be significantly reduced if diagnosis and treatment are properly performed during initial phases of the disease. The current search for biomarkers in early-stage melanomas is a high-priority challenge for physicians and researchers. We aimed to assess the immunoexpression of BRAFV600E and KIT in a case series consisting of 44 early-stage melanomas. Formalin-fixed paraffin-embedded samples were systematically evaluated using a semi-quantitative method based on scores of percentage and intensity for immunostained tumor cells. We observed significant concordance between BRAFV600E and KIT immunoexpression in thin invasive melanomas. Our findings corroborate previous evidence showing abnormal expression of proteins associated with MAPK intracellular signaling pathway in early-stage melanomas.

Citing Articles

The human melanoma proteome atlas-Defining the molecular pathology.

Betancourt L, Gil J, Kim Y, Doma V, Cakir U, Sanchez A Clin Transl Med. 2021; 11(7):e473.

PMID: 34323403 PMC: 8255060. DOI: 10.1002/ctm2.473.

References

Olsen C, Carroll H, Whiteman D . Estimating the attributable fraction for cancer: A meta-analysis of nevi and melanoma. Cancer Prev Res (Phila). 2010; 3(2):233-45. DOI: 10.1158/1940-6207.CAPR-09-0108. View

Shain A, Bastian B . From melanocytes to melanomas. Nat Rev Cancer. 2016; 16(6):345-58. DOI: 10.1038/nrc.2016.37. View

Joyce K, Joyce C, Jones D, Donnellan P, Hussey A, Regan P . An assessment of histological margins and recurrence of melanoma in situ. Plast Reconstr Surg Glob Open. 2015; 3(2):e301. PMC: 4350307. DOI: 10.1097/GOX.0000000000000272. View

Mar V, Liu W, Devitt B, Wong S, Dobrovic A, McArthur G . The role of BRAF mutations in primary melanoma growth rate and survival. Br J Dermatol. 2015; 173(1):76-82. DOI: 10.1111/bjd.13756. View

Ecsedi S, Hernandez-Vargas H, Lima S, Vizkeleti L, Toth R, Lazar V . DNA methylation characteristics of primary melanomas with distinct biological behaviour. PLoS One. 2014; 9(5):e96612. PMC: 4022506. DOI: 10.1371/journal.pone.0096612. View

Montagnani V, Benelli M, Apollo A, Pescucci C, Licastro D, Urso C . Thin and thick primary cutaneous melanomas reveal distinct patterns of somatic copy number alterations. Oncotarget. 2016; 7(21):30365-78. PMC: 5058686. DOI: 10.18632/oncotarget.8758. View

. Genomic Classification of Cutaneous Melanoma. Cell. 2015; 161(7):1681-96. PMC: 4580370. DOI: 10.1016/j.cell.2015.05.044. View

Neiswender J, Kortum R, Bourque C, Kasheta M, Zon L, Morrison D . KIT Suppresses BRAF-Mutant Melanoma by Attenuating Oncogenic RAS/MAPK Signaling. Cancer Res. 2017; 77(21):5820-5830. PMC: 5679278. DOI: 10.1158/0008-5472.CAN-17-0473. View

Rajkumar S, Watson I . Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies. Br J Cancer. 2016; 115(2):145-55. PMC: 4947706. DOI: 10.1038/bjc.2016.195. View

10.

Mihic-Probst D, Shea C, Duncan L, De la Fouchardiere A, Landman G, Landsberg J . Update on Thin Melanoma: Outcome of an International Workshop. Adv Anat Pathol. 2015; 23(1):24-9. DOI: 10.1097/PAP.0000000000000100. View

11.

Posch C, Moslehi H, Sanlorenzo M, Green G, Vujic I, Panzer-Grumayer R . Pharmacological inhibitors of c-KIT block mutant c-KIT mediated migration of melanocytes and melanoma cells in vitro and in vivo. Oncotarget. 2016; 7(29):45916-45925. PMC: 5216770. DOI: 10.18632/oncotarget.10001. View

12.

Chapman P, Hauschild A, Robert C, Haanen J, Ascierto P, Larkin J . Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364(26):2507-16. PMC: 3549296. DOI: 10.1056/NEJMoa1103782. View

13.

Griffin M, Scotto D, Josephs D, Mele S, Crescioli S, Bax H . BRAF inhibitors: resistance and the promise of combination treatments for melanoma. Oncotarget. 2017; 8(44):78174-78192. PMC: 5652848. DOI: 10.18632/oncotarget.19836. View

14.

Bastian B . The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol. 2014; 9:239-71. PMC: 4831647. DOI: 10.1146/annurev-pathol-012513-104658. View